Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial
Jens Y. Humrich, P. Cacoub, Michèlle Rosenzwajg, Fabien Pitoiset, Hang Phuong Pham, Joel Guidoux, David Leroux, Thomas Vazquez, Gabriela Riemekasten, Josef S Smolen, George C. Tsokos, David Klatzmann
Topics & Concepts
MedicinePlaceboClinical endpointInternal medicinePopulationLupus erythematosusClinical trialGastroenterologyImmunologyPathologyAntibodyEnvironmental healthAlternative medicineSystemic Lupus Erythematosus ResearchMultiple Sclerosis Research StudiesRheumatoid Arthritis Research and Therapies